111627-40-8

Basic information

• Product Name: Benzoic acid, 4-(3-chloropropoxy)-3-methoxy-, methyl ester
• CAS NO: 111627-40-8
• Molecular Formula: C12H15ClO4
• Molecular Weight: 258.702
• Mol File: 111627-40-8.mol
• Article Data: 40

Chemical Properties

• CAS DataBase Reference: Benzoic acid, 4-(3-chloropropoxy)-3-methoxy-, methyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: Benzoic acid, 4-(3-chloropropoxy)-3-methoxy-, methyl ester(111627-40-8)
• EPA Substance Registry System: Benzoic acid, 4-(3-chloropropoxy)-3-methoxy-, methyl ester(111627-40-8)

Safety Data

• Hazardous Substances Data: 111627-40-8(Hazardous Substances Data)

Upstream product

• 67-56-1 methanol 
• 121-34-6 3-methoxy-4-hydroxybenzoic acid 
• 109-70-6 1.3-chlorobromopropane 
• 3943-74-6 4-hydroxy-3-methoxybenzoic acid methyl ester 
• 6940-76-7 1-iodo-3-chloro-propane 
• 6702-50-7 3-hydroxy-4-methoxybenzoate 
• 632-02-0 3-chloropropyl p-toluenesulfonate 
• 5137-55-3 Aliquat 336 

Downstream Products

• 151719-68-5 4-(3-Chloropropoxy]-3-methoxybenzoic acid 
• 1188907-05-2 1-(5-tert-butyl-isoxazol-3-yl)-3-{3-[7-(3-chloro-propoxy)-6-methoxy-quinazolin-4-yloxy]-phenyl}-urea 
• 1188907-04-1 1-(5-tert-butylisoxazol-3-yl)-3-(3-(6-methoxy-7-(3-morpholinopropoxy)quinazolin-4-yloxy)phenyl)urea 
• 1320288-30-9 2,4-dichloro-6-methoxy-7-(3-(pyrrolidin-1-yl)propoxy)quinazoline 
• 1320288-52-5 2-(4-cyclohexyl-1,4-diazepan-1-yl)-N-(1-isopropylpiperidin-4-yl)-6-methoxy-7-(3-(pyrrolidin-1-yl)propoxy)quinazolin-4-amine 
• 1320288-54-7 2-(4-(cyclohexylmethyl)-1,4-diazepan-1-yl)-N-(1-isopropylpiperidin-4-yl)-6-methoxy-7-(3-(pyrrolidin-1-yl)propoxy)quinazolin-4-amine 
• 1320288-56-9 N-(1-isopropylpiperidin-4-yl)-6-methoxy-2-(4-phenyl-1,4-diazepan-1-yl)-7-(3-(pyrrolidin-1-yl)propoxy)quinazolin-4-amine 
• 1320288-58-1 2-(4-benzyl-1,4-diazepan-1-yl)-N-(1-isopropylpiperidin-4-yl)-6-methoxy-7-(3-(pyrrolidin-1-yl)propoxy)quinazolin-4-amine 
• 1320288-17-2 N-(1-cyclohexylpiperidin-4-yl)-2-(4-isopropyl-1,4-diazepan-1-yl)-6-methoxy-7-(3-(piperidin-1-yl)propoxy)quinazolin-4-amine 
• 1320288-24-1 methyl 2-amino-5-methoxy-4-[3-(pyrrolidin-1-yl)propoxy]benzoate 
• 1320288-19-4 N-(1-(cyclohexylmethyl)piperidin-4-yl)-2-(4-isopropyl-1,4-diazepan-1-yl)-6-methoxy-7-(3-(piperidin-1-yl)propoxy)quinazolin-4-amine 
• 1320288-48-9 N-(1-cyclohexylpiperidin-4-yl)-6-methoxy-2-(4-methyl-1,4-diazepan-1-yl)-7-(3-(piperidin-1-yl)propoxy)quinazolin-4-amine 
• 1320288-27-4 C₁₇H₂₅N₃O₅ 
• 1320288-29-6 6-methoxy-7-(3-pyrrolidin-1-ylpropoxy)-1H-quinazoline-2,4-dione 

Relevant articles and documents

New 4-N-phenylaminoquinoline derivatives as antioxidant, metal chelating and cholinesterase inhibitors for Alzheimer's disease

A series of new 4-N-phenylaminoquinoline derivatives were designed, synthesized, and their anticholinesterase activities, 1,1-Diphenyl-2-picrylhydrazyl (DPPH) radical scavenging activity, metal-chelating ability were tested. Among them, compounds 11j, 11k and 11l had comparable inhibition activities to reference drug galantamine both in AChE and in BChE. Especially, compound 11j revealed the most potent inhibition to eeAChE and eqBChE with IC50 values of 1.20 μM and 18.52 μM, respectively. Furthermore, both kinetic analysis of AChE inhibition and molecular docking study indicated that compound 11j was mixed-type inhibitor, binding simultaneously to the catalytic anionic site (CAS) and the peripheral anionic site (PAS) of AChE, and propidium iodide displacement assay showed significant displacement of propidium iodide with compound 11k (25.80%) from PAS of eeAChE. More importantly, compound 11l displayed excellent DPPH radical scavenging activity (84% at 1 mg/mL), and its EC50 value was 0.328 μM. In addition, compounds 11a, 11j, 11k and 11l exhibited obvious biometal chelating abilities toward Al3+, Fe2+, Cu2+ and Zn2+ ions. Taken together, 4-N-phenylaminoquinoline derivatives targeting multiple pathogenetic factors deserve further investigation for treatment of AD.

Design, synthesis, evaluation and molecular modeling study of 4-N-phenylaminoquinolines for Alzheimer disease treatment

Dual binding site acetylcholinesterase (AChE) inhibitors and butyrylcholinesterase (BChE) inhibitors have recently emerged as two classes of new anti-Alzheimer agents to positively modify the disease's course. In this work, a new series of 4-N-phenylaminoquinolines was synthesized and evaluated for their abilities to inhibit AChE and BChE. Compound 11b showed significant inhibitory activities on AChE and BChE with IC50 values of 0.86 and 2.65 μM, respectively, a lot better than that of reference drug galanthamine. Furthermore, docking study showed that compound 11b interacted simultaneously not only with active and peripheral sites of AChE, but also with all five regions of BChE active site. These findings suggest that these derivatives could be regarded as promising starting points for further drug discovery developments.

Development of a series of novel 4-anlinoquinazoline derivatives possessing quinazoline skeleton: Design, synthesis, EGFR kinase inhibitory efficacy, and evaluation of anticancer activities in?vitro

4-anilinoquinazoline-based derivatives represent an attractive scaffold for small molecular EGFR-TKIs in the field of medicinal chemistry. A series of novel heterocyclic substituted derivatives have been designed, synthesized and evaluated their antitumor

A new and practical synthesis of bosutinib

New and improved synthetic route of bosutinib is described on a decagram scale. An intramolecular cyclization of 3-amino-2-(2-bromobenzoyl)-acrylonitrile (22) in K2CO3/DMF condition to form the key 3-cyano-4-hydroxyquinoline intermediate (13) is adopted as the key step. Bosutinib is obtained in 13.7% yield over ten steps and 98.9% purity (HPLC), which make it as a process of cost effective, environmentally friendly and feasible for scale-up operation.

1,3-disubstituted urea and thiourea derivative and application thereof

The invention discloses a 1,3-disubstituted urea and thiourea derivative and application thereof in the field of pharmaceutical chemistry. A structural formula of the derivative is as shown in the specification, and the derivative gives play to an antitumor function through inhibition of tyrosine protein kinase activity, wherein main tyrosine protein kinase inhibited by the derivative includes c-Met, IGF-1R, Src, c-Kit and the like. The derivative can be used for preparation of medicines for preventing or treating hyperplastic diseases, lung cancers, liver cancers, gastric cancers, colon cancers and breast cancers.